Research programme: albumin and antibody drug conjugates - CytRx

Drug Profile

Research programme: albumin and antibody drug conjugates - CytRx

Alternative Names: DK 049

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytRx Corporation
  • Class Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Research Liver cancer

Most Recent Events

  • 08 Nov 2017 CytRx Corporation announces intention to file an IND application with US FDA for Cancer in 2018
  • 02 Oct 2017 Albumin and antibody drug conjugates - CytRx is available for licensing as of 02 Oct 2017. http://www.cytrx.com
  • 02 Oct 2017 CytRx intends to seek breakthrough therapy designation from US FDA for its LADR™ based antibody drug conjugate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top